Preoperative Topical Gatifloxacin on Anterior Chamber Cultures After Cataract Surgery
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00335231 |
Recruitment Status :
Withdrawn
(Protocol changes underway. Trial never started)
First Posted : June 9, 2006
Last Update Posted : May 2, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Postoperative endophthalmitis, a possible severe complication of cataract surgery, is an infection of the anterior chamber of the eye caused by bacterial contamination and colonization through surgical incisions. Bacteria are thought to originate mainly from the patient's skin and studies show that bacteria are commonly found in the anterior chamber following surgery. However, innate immune defences are usually able to control and eliminate bacterial growth before postoperative endophthalmitis occurs. Also, due to the low incidence of postoperative endophthalmitis, it is difficult to accurately evaluate preventative methods. This study will examine the efficacy of topical preoperative administration of gatifloxacin (a new fourth generation fluoroquinolone antibiotic) on reduction of bacterial contamination of the anterior chamber following cataract surgery. If the antibiotic is shown to lower bacteria count in cultures from anterior chamber fluid, it has the potential to lower the incidence of postoperative endophthalmitis.
Patients undergoing cataract surgery will be notified and asked to participate in the study by the physician in advance of the surgery, provided they do not possess any exclusion criteria. The participants will be randomly split into two groups; one group will receive topical application of gatifloxacin prior to surgery, while the other group will receive no eye drops. During surgery, a small sample of anterior chamber fluid will be removed from the eye and cultured in both broth and enrichment media for all subjects. Bacterial growth, i.e., colony forming units (CFUs), will be used as an indicator of the bacterial contamination of the fluid.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Endophthalmitis | Drug: gatifloxacin ophthalmic (ZYMAR) | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 0 participants |
Allocation: | Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Prevention |
Official Title: | The Effect of Preoperative Topical Gatifloxacin on Anterior Chamber Sample Cultures After Cataract Surgery. |
Study Start Date : | June 2006 |
Actual Primary Completion Date : | June 2013 |
Actual Study Completion Date : | June 2013 |

Arm | Intervention/treatment |
---|---|
Experimental: gatifloxacin
one group will receive topical application of gatifloxacin prior to surgery,
|
Drug: gatifloxacin ophthalmic (ZYMAR) |
No Intervention: no eye drops
this group will receive no eye drops.
|
- Difference in bacterial colony forming units (CFUs) between treatment (gatifloxacin) and no treatment group
- Bacterial sensitivity
- Patient comfort

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Cataract surgery on first eye (i.e., first cataract surgery.
Exclusion Criteria:
- uveitis,
- herpetic eye disease,
- corneal ulceration,
- severe blepharitis,
- past trauma to the eye,
- complicated cataract surgery (e.g., posterior capsule rupture),
- previous intraocular surgeries.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00335231
Canada, Ontario | |
Hotel Dieu Hospital | |
Kingston, Ontario, Canada, K7L 5G2 |
Principal Investigator: | Sherif El-Defrawy, MD PhD FRCSC | Queen's University, Hotel Dieu Hospital, Kingston General Hospital |
Responsible Party: | Queen's University |
ClinicalTrials.gov Identifier: | NCT00335231 |
Other Study ID Numbers: |
QUEENS-SRE-3 |
First Posted: | June 9, 2006 Key Record Dates |
Last Update Posted: | May 2, 2018 |
Last Verified: | April 2018 |
Post-cataract surgery endophthalmitis |
Endophthalmitis Cataract Capsule Opacification Lens Diseases Eye Diseases Eye Infections Infection Gatifloxacin Anti-Bacterial Agents |
Anti-Infective Agents Ophthalmic Solutions Pharmaceutical Solutions Topoisomerase II Inhibitors Topoisomerase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents |